Nordic countries have had some of the highest rates of biosimilar use, and extensive registry data in these countries also allow for observational studies of biosimilar use in real-world clinical practice. A new study used data from 5 such registries—which included more than 2000 patients with spondyloarthritis—to assess retention rates for those treated with biosimilars or reference products of etanercept and infliximab.
Nordic countries have had some of the highest rates of biosimilar use, and extensive registry data in these countries also allow for observational studies of biosimilar use in real-world clinical practice. A new paper, published in RMD Open, used data from 5 such registries—which included more than 2000 patients with spondyloarthritis—to assess retention rates for those treated with biosimilars or reference products of etanercept and infliximab.
In the study, biologic-naïve patients with spondyloarthritis in the 5 Nordic nations who started treatment with reference etanercept (Enbrel), reference infliximab (Remicade), biosimilar etanercept (Benepali), or biosimilar infliximab (Remsima) between 2014 and 2017 were included. Data were derived from national biologics registers in Sweden (ARTIS), Denmark (DANBIO), Finland (ROB-FIN), and Iceland (ICEBIO), as well as the regional biologics register in Norway (NOR-DMARD).
In total, 2334 patients were included; 1319 patients received infliximab (24% reference, 76% biosimilar), and 1015 patients received etanercept (49% reference, 51% biosimilar). Apart from higher concomitant disease-modifying antirheumatic drug use in the reference cohorts, there were no clinically relevant differences in baseline characteristics among the patients who started therapy with reference drugs versus biosimilars.
The investigators found that retention among patient receiving reference and biosimilar drugs was similar at 1 year:
Two-year data were available for infliximab, and also showed similar retention:
Proportional hazard analyses showed a 5% decrease in risk of discontinuation favoring biosimilar infliximab over the reference, and a 15% decrease for biosimilar etanercept over its reference; however, the 95% CIs did not show a statistically significant decrease in risk.
While the study was limited by the fact that it did not allow for a direct comparison of efficacy, and the fact that not all countries contributed to all treatment arms due to biosimilar availability, “a strength of the present study is that confounders, such as nocebo related to the context of switching from a stable ongoing treatment with an originator to its (cheaper) biosimilar, should be minimized in a bionaïve population. Another strength is that the pooling of data from the different countries ought to reduce the risk of country-specific channeling towards originators or biosimilars,” write the authors.
Reference
Lindström U, Glintborg B, Di Giuseppe D, et al. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis. RMD Open 2019;5:e001079. doi: 10.1136/rmdopen-2019-001079.
Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD
May 18th 2024A real-world study in Spain on inflammatory bowel disease (IBD) patients found no meaningful changes in clinical or biochemical markers or differences in effectiveness between the adalimumab originator and the biosimilar MSB11022 (Idacio; Fresenius Kabi) in adalimumab-naïve patients.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Panelists Call for Consistent Education, Support to Improve Patient Comfort With Biosimilars
May 15th 2024At the Festival of Biologics USA, panelists stressed the need for patient-centered communication and education to boost comfort with biosimilars, emphasizing consistent support from health care providers despite restrictive payer policies.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.